FDA panel votes 9-2 Heartware's (HTWR) implantable pump devices benefits outweigh risks
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Join SI Premium – FREE
FDA panel votes 9-2 Heartware's (Nasdaq: HTWR) implantable pump devices benefits outweigh risks
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
- C4 Therapeutics to present cemsidomide biomarker data at myeloma meeting
- BridgeBio to present infigratinib data at ESPE meeting in September
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
